CheezhengTTM(SZ:002287) Chang Jiang Shang Bao·2025-07-29 08:53Core Viewpoint - Qizheng Tibetan Medicine (002287.SZ) has reversed its operating performance, showing significant growth in revenue and net profit in the first half of 2025 compared to the previous year [1][2]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.175 billion yuan, a year-on-year increase of 16.36%, and a net profit attributable to shareholders of 358 million yuan, up 9.94% [1]. - The company's net profit for the second quarter reached 282 million yuan, marking a year-on-year increase of 23.68%, which is the best performance for the same period in the last three years [2]. - The first quarter of 2025 saw operating revenue of 403 million yuan, a 10.39% increase, but net profit decreased by 22.35% [1]. Historical Performance - Since its listing in 2009, Qizheng Tibetan Medicine has shown a consistent growth trend, with operating revenue increasing from 469 million yuan in 2009 to 2.338 billion yuan in 2024 [2]. - Cumulative net profit since listing amounts to 5.515 billion yuan [3]. Shareholder Returns - The company has actively returned profits to shareholders, distributing a total of 2.895 billion yuan in cash dividends over the past 16 years, with an average dividend payout ratio of 52.49% [3]. - The dividend-to-financing ratio since listing stands at 225.41% [4]. Financial Health - As of the end of the first quarter of 2025, the company's debt-to-asset ratio was 39.42%, with monetary funds of 523 million yuan and financial assets of 2.674 billion yuan [4][5].